GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Paratek Pharmaceuticals Inc (NAS:PRTK) » Definitions » Shiller PE Ratio

Paratek Pharmaceuticals (Paratek Pharmaceuticals) Shiller PE Ratio : (As of May. 05, 2024)


View and export this data going back to 2006. Start your Free Trial

What is Paratek Pharmaceuticals Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Paratek Pharmaceuticals Shiller PE Ratio Historical Data

The historical data trend for Paratek Pharmaceuticals's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Paratek Pharmaceuticals Shiller PE Ratio Chart

Paratek Pharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Paratek Pharmaceuticals Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Paratek Pharmaceuticals's Shiller PE Ratio

For the Biotechnology subindustry, Paratek Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Paratek Pharmaceuticals's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Paratek Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Paratek Pharmaceuticals's Shiller PE Ratio falls into.



Paratek Pharmaceuticals Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Paratek Pharmaceuticals's E10 for the quarter that ended in Jun. 2023 is calculated as:

For example, Paratek Pharmaceuticals's adjusted earnings per share data for the three months ended in Jun. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Jun. 2023 (Change)*Current CPI (Jun. 2023)
=-0.25/128.7287*128.7287
=-0.250

Current CPI (Jun. 2023) = 128.7287.

Paratek Pharmaceuticals Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201309 -3.000 98.790 -3.909
201312 -3.480 98.326 -4.556
201403 -1.800 99.695 -2.324
201406 -2.160 100.560 -2.765
201409 -5.160 100.428 -6.614
201412 -0.377 99.070 -0.490
201503 -0.740 99.621 -0.956
201506 -0.960 100.684 -1.227
201509 -1.330 100.392 -1.705
201512 -1.200 99.792 -1.548
201603 -1.780 100.470 -2.281
201606 -1.690 101.688 -2.139
201609 -1.040 101.861 -1.314
201612 -1.120 101.863 -1.415
201703 -1.140 102.862 -1.427
201706 -0.660 103.349 -0.822
201709 -0.770 104.136 -0.952
201712 -0.780 104.011 -0.965
201803 -0.910 105.290 -1.113
201806 -0.940 106.317 -1.138
201809 -1.010 106.507 -1.221
201812 -0.710 105.998 -0.862
201903 -1.100 107.251 -1.320
201906 -1.020 108.070 -1.215
201909 -1.000 108.329 -1.188
201912 -0.810 108.420 -0.962
202003 -0.660 108.902 -0.780
202006 -0.530 108.767 -0.627
202009 -0.460 109.815 -0.539
202012 -0.540 109.897 -0.633
202103 -0.390 111.754 -0.449
202106 0.200 114.631 0.225
202109 -0.370 115.734 -0.412
202112 -0.660 117.630 -0.722
202203 -0.350 121.301 -0.371
202206 -0.330 125.017 -0.340
202209 -0.380 125.227 -0.391
202212 -0.120 125.222 -0.123
202303 -0.350 127.348 -0.354
202306 -0.250 128.729 -0.250

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Paratek Pharmaceuticals  (NAS:PRTK) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Paratek Pharmaceuticals Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Paratek Pharmaceuticals's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Paratek Pharmaceuticals (Paratek Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
75 Park Plaza, 4th Floor, Boston, MA, USA, 02116
Paratek Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's medical research is based on tetracycline chemistry and biology to create two antibacterials: omadacycline and sarecycline. NUZYRA (Omadacycline) is an antibacterial for skin infections and treatment of community-acquired bacterial pneumonia. SEYSARA (Sarecycline) is designed for use in the treatment of acne and rosacea. Paratek Pharmaceuticals is also involved in research to treat multiple sclerosis, spinal muscular atrophy, and systemic inflammatory diseases such as rheumatoid arthritis and inflammatory bowel diseases.
Executives
Minnie Baylor-henry director C/O SCPHARMACUETICALS, INC., 2400 DISTRICT AVENUE SUITE 310, BURLINGTON MA 01803
Kristine Peterson director AMARIN CORPORATION, MYSTIC PACKER BLDG., 12 ROOSEVELT AVENUE, MYSTIC CT 06355
Timothy R Franson director 320 WAKARA WAY, SALT LAKE CITY UT 84108
Jeffrey Stein director 6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121
Thomas John Dietz director C/O TRANSCEPT PHARMACEUTICAL, INC., 1003 W. CUTTING BLVD, STE 110, PT. RICHMOND CA 94804
Evan Loh director, officer: CEO 75 KNEELAND STREET, BOSTON MA 02111
William M. Haskel officer: CLO, General Counsel & Sec. ONE MEADOWLANDS PLAZA, EAST RUTHERFORD NJ 07073
Adam Woodrow officer: President & Chief Commercial C/O PARATEK PHARMACEUTICALS, INC., 75 KNEELAND STREET, BOSTON MA 02111
Randall B. Brenner officer: Chief Development & Regulatory C/O PARATEK PHARMACEUTICALS, INC., 75 PARK PLAZA, 4TH FLOOR, BOSTON MA 02116
Robert S Radie director 101 LINDENWOOD DRIVE, SUITE 225, MALVERN PA 19355
Rolf K Hoffmann director LORBEERWEG 7, WEGGIS V8 CH-6353
Michael Bigham director, officer: Exec. Chairman of the Board 890 WINTER STREET, WALTHAM MA 02451
James D Dondero 10 percent owner 300 CRESCENT COURT, SUITE 700, DALLAS TX 75201
Douglas W. Pagan officer: Chief Financial Officer 75 KNEELAND STREET, BOSTON MA 02111
Omega Fund Iv, L.p. 10 percent owner 888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199

Paratek Pharmaceuticals (Paratek Pharmaceuticals) Headlines

From GuruFocus